Both acute and repeated exposure to NMDAR antagonists induces schizophrenia-like symptoms in humans39, 40 and acute administration of the NMDAR antagonist ketamine can exacerbate symptoms in schizophrenia patients.41, 42 Furthermore, a multitude of preclinical studies suggest that both acute and repeated NMDAR antagonist administration induces behavioral deficits with translational relevance to schizophrenia.26, 43, 44, 45 However, whether Disc1 truncation impacts on NMDAR function in vivo is currently unknown. Here, DISC1 is linked to schizophrenia.